{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/f5f6e2cc-06d4-4684-8d26-bf12e13cbbd2/HTML","dcterms:extent":"23 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/be7e4d59-e002-4017-ada0-ed33da5e30cc/PDF","dcterms:extent":"67 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/393766a3-afda-40a2-9cd8-6b4fd5b7d0d0/TEXT","dcterms:extent":"21 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-MWPKWMXA","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2010","dc:creator":["Berginc, Katja","Kristl, Albin"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:61"},{"@xml:lang":"sl","#text":"str. 171-175"}],"dc:identifier":["ISSN:0014-8229","COBISSID:2827889","URN:URN:NBN:SI:doc-MWPKWMXA"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"citokromi"},{"@xml:lang":"sl","#text":"česen"},{"@xml:lang":"sl","#text":"farmacevtski preparati"},{"@xml:lang":"sl","#text":"interakcije"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Farmakološki učinki česnovih pripravkov in njihove interakcije z zdravilnimi učinkovinami| The pharmacological effects of garlic supplements and their interactions with prescribed therapy|"},"dc:description":[{"@xml:lang":"sl","#text":"The consumption of commercially available garlic supplements especially by chronic patients is continuously rising due to disease preventing effects, recognized in numerous preclinical and clinical studies. However, combining inconventional therapy utilized drugs with garlic phytochemicals can lead to serious pharmacokinetic and pharmacodynamic interactions. Namely, in some cases significant plasma profile changes of applied drugs and their metabolites, caused by intestinal and hepatic CYP inhibition and/or altered efflux membrane transporter activity, have been recognized in the presence of garlic phytochemicals leading to therapeutic failure or toxic side effects. There are also reports on pharmacodynamic interactions between drugs with narrow therapeutic window (i.e. warfarin) and garlic. Therefore combining garlic supplements and certain drugs should be closely monitored or in some cases even discontinued"},{"@xml:lang":"sl","#text":"Zaradi farmakoloških učinkov česnovih pripravkov, dokazanih v predkliničnih in kliničnih študijah, po tovrstnih pripravkih posegajo številni kronični bolniki brez vednosti o potencialno nevarnih farmakokinetskih in farmakodinamskih interakcijah, ki se lahko razvijejo ob sočasno predpisani terapiji. Inhibicija encimov iz družine citokromov in/ali spremenjena aktivnost sekretornih prenašalcev v jetrih in črevesju ob prisotnosti nekaterih oeesnovih sestavin lahko pomembno spremeni profil plazemskih koncentracij apliciranih učinkovin in njihovih metabolitov, kar lahko vodi v terapevtsko neučinkovitost ali v toksične učinke. Zasledimo lahko tudi poročila o farmakodinamskih interakcijah med česnovimi pripravki in nekaterimi učinkovinami z ozkim terapevtskim oknom (npr. varfarinom). Zaradi naštetega se sočasna uporaba česnovih pripravkov z nekaterimi učinkovinami odsvetuje oz. je priporočeno terapevtsko spremljanje plazemskih koncentracij učinkovin"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-MWPKWMXA","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-MWPKWMXA"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-MWPKWMXA/be7e4d59-e002-4017-ada0-ed33da5e30cc/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-MWPKWMXA/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-MWPKWMXA"}}}}